Skip to content
NewsBlazeIN – Lifestyle
Author:
Knight Therapeutics
Knight Therapeutics Announces Regulatory Supplemental Submission of MINJUVI® (tafasitamab) for Follicular Lymphoma in Argentina and Mexico
March 17, 2026
Notice of Knight Therapeutics’ Fourth Quarter and Year End 2025 Results Conference Call
March 12, 2026
←
Previous Page
1
2